X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2023/05/04/2661990/0/en/Galapagos-announces-first-quarter-2023-financial-results.html
https://www.globenewswire.com/news-release/2023/04/26/2655620/0/en/Galapagos-initiates-Phase-3-program-with-filgotinib-in-patients-with-active-axial-spondyloarthritis.html
https://www.glpg.com/press-release/3766/galapagos-announces-topline-results-from-phase-3-diversity-trial-of-filgotinib-in-crohn-s-disease
https://www.biopharmadive.com/news/ema-recommends-jak-inhibitors-restrictions/636343/
https://www.glpg.com/press-release/3705/galapagos-announces-strategy-to-accelerate-innovation-and-reports-strong-third-quarter-2022-results
https://www.europeanpharmaceuticalreview.com/news/175849/jak-inhibitors-unsafe-for-cardiovascular-cancer-risk-prac/
https://endpts.com/ema-limits-use-of-jak-inhibitors-for-at-risk-groups-in-wake-of-safety-concerns/
https://www.pharmiweb.com/press-release/2022-10-11/once-daily-jyseleca-filgotinib-to-be-made-available-on-the-nhs-in-scotland-for-people-with-moderate-rheumatoid-arthritis-ra
https://www.globenewswire.com/news-release/2022/01/18/2368869/0/en/JYSELECA-FILGOTINIB-LICENSED-FOR-THE-TREATMENT-OF-ADULT-PATIENTS-WITH-MODERATELY-TO-SEVERELY-ACTIVE-ULCERATIVE-COLITIS-IN-GREAT-BRITAIN.html
https://www.globenewswire.com/news-release/2021/11/15/2334506/0/en/Jyseleca-filgotinib-approved-in-the-European-Union-for-the-treatment-of-ulcerative-colitis.html
https://www.pharmacompass.com/pdf/news/galapagos-presents-new-data-from-the-selection-phase-3-program-at-the-united-european-gastroenterology-week-uegw-2021-congress-1635519599.pdf
https://www.globenewswire.com/news-release/2021/09/17/2299005/0/en/GALAPAGOS-ANNOUNCES-POSITIVE-CHMP-OPINION-FOR-JYSELECA-FILGOTINIB-FOR-THE-TREATMENT-OF-ADULTS-WITH-MODERATELY-TO-SEVERELY-ACTIVE-ULCERATIVE-COLITIS.html
http://www.pharmafile.com/news/587839/nhs-scotland-makes-rheumatoid-arthritis-drug-available
https://www.globenewswire.com/news-release/2021/06/22/2251348/0/en/Galapagos-announces-departure-of-CSO-Piet-Wigerinck-later-this-year.html
https://endpts.com/galapagos-posts-a-safety-win-for-filgotinib-but-is-it-too-little-too-late-bio-techne-inks-320m-molecular-diagnostics-buyout/
https://www.biopharmadive.com/news/galapagos-reports-long-awaited-safety-data-for-inflammation-drug/596140/
http://www.pharmafile.com/news/569315/nice-recommends-rheumatoid-arthritis-drug-jyseleca-nhs-use
http://www.pharmatimes.com/news/nice_publishes_final_guidance_backing_jyseleca_for_rheumatoid_arthritis_1361676
https://www.fiercepharma.com/pharma/gilead-s-filgotinib-dream-nears-end-partnership-rebuild-blow-to-ceo-s-diversification-plan
https://endpts.com/its-official-gileads-dan-oday-pulls-the-plug-on-the-lions-share-of-their-filgotinib-collaboration-as-the-fda-erects-a-high-safety-barrier/
http://www.pharmatimes.com/news/ema_begins_evaluation_of_filgotinib_for_ulcerative_colitis_1355832
https://endpts.com/news-briefing-gilead-submits-filgotinib-to-european-regulators-for-uc-gw-pharmaceuticals-launches-phiii-trial-for-ms-candidate-made-with-cannabis-extracts/
https://endpts.com/gilead-hits-the-brakes-on-a-trifecta-of-mid-and-late-stage-studies-for-their-troubled-filgotinib-program-its-up-to-the-fda-now/
https://www.gilead.com/news-and-press/press-room/press-releases/2020/10/phase-2b3-trial-shows-efficacy-of-filgotinib-for-the-induction-and-maintenance-of-remission-in-moderately-and-severely-active-ulcerative-colitis
https://seekingalpha.com/news/3621410-gilead-and-galapagoss-filgotinib-shows-sustained-efficacy-in-ulcerative-colitis-study
https://www.ema.europa.eu/en/documents/overview/jyseleca-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/jyseleca-epar-medicine-overview_en.pdf
http://www.pharmatimes.com/news/gileads_oral_jak_inhibitor_filgotinib_wins_eu_approval_1351635
https://www.fiercepharma.com/pharma-asia/gilead-s-rheumatoid-arthritis-jyseleca-after-cold-shoulder-from-fda-wins-global-first
https://seekingalpha.com/pr/18020594-european-commission-grants-marketing-authorization-for-jyseleca-filgotinib-for-treatment-of
https://www.reuters.com/article/us-gilead-sciences-stocks/gilead-shares-slide-after-fda-knocks-back-rheumatoid-arthritis-drug-idUSKCN25F1PI
https://endpts.com/fda-hands-gilead-a-stunning-rejection-for-blockbuster-ra-candidate-filgotinib-dealing-ceo-oday-a-major-setback/
https://www.raps.org/news-and-articles/news-articles/2020/7/ema-thumbs-up-for-11-down-for-2-new-medicines
https://www.fiercebiotech.com/biotech/gilead-builds-case-for-filgotinib-active-psoriatic-arthritis
https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/filgotinib-demonstrates-durable-efficacy-and-consistent-safety-profile-at-52-weeks-in-finch-1-and-3-studies-in-rheumatoid-arthritis#:~:text=Filgotinib%20Demonstrates%20Durable%20Efficacy%20and%20Consistent%20Safety%20Profile%20at%2052,3%20Studies%20in%20Rheumatoid%20Arthritis&text=FOSTER%20CITY%2C%20Calif.&text=The%20data%20demonstrate%20sustained%20efficacy,treatment%20across%20RA%20patient%20populations.
https://endpts.com/gilead-woos-filgotinib-clinical-investigator-from-stanford-to-lead-the-charge-on-nash-inflammatory-diseases/
https://www.fiercebiotech.com/biotech/gilead-s-filgotinib-phase-3-hits-primary-endpoint-but-details-dampen-hopes
https://www.biopharmadive.com/news/galapagos-ceo-coronavirus-filgotinib-enrollment-pause/574860/
https://www.fiercepharma.com/marketing/gilead-leans-data-focus-to-launch-filgotinib-into-jam-packed-ra-market-exec
http://www.pharmatimes.com/news/disappointing_efficacy_for_asit_biotechs_pollen_drug_1318938
https://www.businesswire.com/news/home/20191109005041/en/New-Data-Filgotinib-Rheumatoid-Arthritis-RA-Demonstrate/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
Market Place
Share 
